These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2002 related articles for article (PubMed ID: 30660004)

  • 21. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
    Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
    Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
    Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
    Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
    Gote V; Sharma AD; Pal D
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.
    Cheung A; Chenoweth AM; Johansson A; Laddach R; Guppy N; Trendell J; Esapa B; Mavousian A; Navarro-Llinas B; Haider S; Romero-Clavijo P; Hoffmann RM; Andriollo P; Rahman KM; Jackson P; Tsoka S; Irshad S; Roxanis I; Grigoriadis A; Thurston DE; Lord CJ; Tutt ANJ; Karagiannis SN
    Clin Cancer Res; 2024 Aug; 30(15):3298-3315. PubMed ID: 38772416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.
    Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R
    Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
    Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
    Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
    Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
    Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 101.